{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-012635","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.305318+00:00","generated_at":"2026-06-12T18:46:35.422371+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Biosciences Q2 net revenue $134.2M, up 25% YoY; board approves $125M buyback","bullets":["Q2 net revenue $134.2M vs $107.0M YoY (+25%); GAAP net income $34.3M ($0.56 diluted EPS).","Non-GAAP adjusted net income $45.9M ($0.76 diluted EPS) vs $34.7M ($0.57) YoY.","Average patients on WAKIX ~5,450, up ~350 sequentially; exited Q2 with ~5,600 patients.","Phase 3 IH INTUNE study fully enrolled; topline data expected Q4 2023. PWS Phase 3 study to initiate Q4 2023.","Board authorized $125M share repurchase program with no expiration date."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-012635","json":"https://secwatch.observer/filing/0001558370-23-012635.json","markdown":"https://secwatch.observer/filing/0001558370-23-012635.md","text":"https://secwatch.observer/filing/0001558370-23-012635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023012635/0001558370-23-012635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023012635/hrmy-20230801x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T18:46:35.422371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"187bc61a1c2d8da16b2f19754f96b601ea20b9ad","claim":"Harmony Biosciences Holdings, Inc. reported quarter ended June 30, 2023 results: net income 34.3 million, EPS 0.56.","evidence_excerpt":"Net product revenues for the quarter ended June 30, 2023 were $134.2 million, compared to $107.0 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023012635/0001558370-23-012635-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"34.3 million"},{"label":"EPS","value":"0.56"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"187bc61a1c2d8da16b2f19754f96b601ea20b9ad","claim":"Harmony Biosciences Holdings, Inc. reported quarter ended June 30, 2023 results: net income 34.3 million, EPS 0.56.","evidence_excerpt":"GAAP net income for the quarter ended June 30, 2023, was $34.3 million, or $0.56 earnings per diluted share, compared to GAAP net income of $23.5 million, or $0.39 earnings per diluted share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023012635/0001558370-23-012635-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"34.3 million"},{"label":"EPS","value":"0.56"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}